Peripheral Artery Disease

Peripheral Artery Disease (PAD) affects 8 to 12 million Americans and results in limb amputation or other severe outcomes, including death. Peripheral Artery Disease is similar to Coronary Artery Disease. Artery walls become clogged with fatty deposits and affect blood circulation in the legs and feet.

Typically a patient will experience cramping or fatigue in the legs and buttocks during activity. This is often referred to as "intermittent claudication." People with PAD have a higher risk of death from stroke and heart attack, due to the risk of blood clots.

Drugs that can prevent blood from clotting are used in patients with PAD. The most common types of drugs used include aspirin, heparin, clopidogrel (PLAVIX), ticlopidine, or abciximab.  As with coronary artery disease, cardiologists often perform angioplasties to help widen the plaque-filled peripheral arteries.

Another approach, again similar to the treatment for blocked coronary arteries, is to perform a bypass graft surgery using either a vein from another part of the body or a synthetic blood vessel.

Liprostin Potential Healing Process

Prostaglandin E-1 (PGE-1) has been shown to be a potent vasodilator and down regulates the immune response, among other properties. The liposomal formulation of PGE-1 is what Endovasc believes will change the drug’s dynamics and improve its therapeutic index.